Bill > HR8920

This bill, the Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020, establishes a program to develop antimicrobial innovations targeting the most challenging pathogens and most threatening infections. The key provisions of the bill include: 1) Establishing a Committee on Critical Need Antimicrobials to develop a list of prioritized infections for which new antimicrobial drug development is needed, and to develop regulations outlining favored characteristics of critical need antimicrobial drugs that will adjust the monetary value of subscription contracts. 2) Allowing the Secretary to provide transitional subscription contracts of up to $1 billion to antimicrobial developers prior to the finalization of the subscription contract regulations. 3) Creating a process for antimicrobial drug sponsors to apply for their drug to be designated as a "critical need antimicrobial" eligible for a subscription contract, which would be in effect for 10 years. 4) Establishing subscription contracts, worth between $750 million and $3 billion, for the purchase of critical need antimicrobial drugs, with the contract amount based on the drug's favored characteristics. 5) Requiring the Secretary to establish a hospital grant program to support efforts to judiciously use antimicrobial drugs, and to enhance surveillance and reporting of antibiotic use and resistance. 6) Appropriating $11 billion to carry out the Act.